Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1121-1127

  Keller V Amsberg, Gunhild ^a   Brümmendorf, Tim H ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

BCR ABL 1; bosutinib; chronic myeloid leukemia; dasatinib; imatinib; nilotinib; point mutation; SRC; SRC ABL kinase inhibitor; tyrosine kinase

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LEUKEMOGENESIS; MINIMUM INHIBITORY CONCENTRATION; MUSCLE CRAMP; MYALGIA; NAUSEA; NONHUMAN; PLEURA EFFUSION; PRURITUS; REVIEW; SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANILINE COMPOUNDS; BENZAMIDES; BIOLOGICAL AVAILABILITY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GASTROINTESTINAL DISEASES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NITRILES; PHARMACOVIGILANCE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 84867959732     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.84     Document Type: Review

References (45)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405), 290-293 (1973).
2. Sattler M, Scheijen B, Weisberg E, Griffin JD. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv. Exp. Med. Biol. 532, 121-140 (2003). (Pubitemid 37176784)
3. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56(1), 100-104 (1996).
4. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21(8), 1637-1647 (2003). (Pubitemid 46594119)
5. O'Brien SG, Guilhot F, Goldman JM et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) Treated with Imatinib (IM). Am. Soc. Hematol. Abstract 86 (2008).
6. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood 99(10), 3530-3539 (2002). (Pubitemid 34534519)
7. Deininger M, O'Brien SG, Guilhot F et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114(22), Abstract 1126 (2009).
8. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7), 2640-2653 (2005). (Pubitemid 40446252)
9. Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11), 4611-4614 (2003). (Pubitemid 36857835)
10. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682), 399-401 (2004). (Pubitemid 38938156)
11. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354(24), 2542-2551 (2006). (Pubitemid 43882350)
12. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6), 2303-2309 (2007). (Pubitemid 46425867)
13. Gambacorti-Passerini C, Cortes JE, Kim H et al. Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. J. Clin. Oncol. 29(Suppl.), Abstract 6509 (2011).
14. Boschelli DH, Ye F, Wang YD et al. Optimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 44(23), 3965-3977 (2001). (Pubitemid 33051486)
15. Boschelli DH. Exploitation of the 3-quinolinecarbonitrile template for SRC tyrosine kinase inhibitors. Curr. Top. Med. Chem. 8(10), 922-934 (2008). (Pubitemid 351984713)
16. Levinson NM, Boxer SG. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS ONE 7(4), e29828 (2012).
17. Puttini M, Coluccia AM, Boschelli F et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinibresistant Bcr-Abl+ neoplastic cells. Cancer Res. 66(23), 11314-11322 (2006). (Pubitemid 46009962)
18. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13 513-609 (1997). (Pubitemid 28034534)
19. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22(4), 337-358 (2003). (Pubitemid 36791891)
20. Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med. Chem. 7(6), 651-659 (2007). (Pubitemid 350237770)
21. Li S. Src-family kinases in the development and therapy of Philadelphia chromosomepositive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk. Lymphoma 49(1), 19-26 (2008). (Pubitemid 351146878)
22. Laneuville P. Abl tyrosine protein kinase. Semin. Immunol. 7(4), 255-266 (1995).
23. Pendergast AM. Nuclear tyrosine kinases: from Abl to WEE1. Curr. Opin. Cell Biol. 8(2), 174-181 (1996). (Pubitemid 26109090)
24. Chung SW, Daniel R, Wong BY, Wong PM. The ABL genes in normal and abnormal cell development. Crit. Rev. Oncog. 7(1-2), 33-48 (1996). (Pubitemid 27238845)
25. Golas JM, Arndt K, Etienne C et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63(2), 375-381 (2003). (Pubitemid 36152495)
26. Remsing Rix LL, Rix U, Colinge J et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23(3), 477-485 (2009).
27. Mancini M, Brusa G, Zuffa E et al. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. Leuk. Res. 31(7), 979-987 (2007). (Pubitemid 46856724)
28. Redaelli S, Piazza R, Rostagno R et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 27(3), 469-471 (2009).
29. Cortes JE, Maru A, De Souza CAA et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia: results from the BELA trial. J. Clin. Oncol. doi:10.1200/JCO.2011. 38.7522 (2012) (Epub ahead of print).
30. Cortes JE, Kantarjian HM, Brümmendorf TH et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17), 4567-4576 (2011).
31. Khoury HJ, Cortes JE, Kantarjian HM et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15), 3403-3412 (2012).
32. Bartolovic K, Balabanov S, Hartmann U et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103(2), 523-529 (2004). (Pubitemid 38140082)
33. Brave M, Goodman V, Kaminskas E et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 14(2), 352-359 (2008). (Pubitemid 351226100)
34. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitorinduced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2), 261-263 (2009).
35. Bantscheff M, Eberhard D, Abraham Y et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25(9), 1035-1044 (2007).
36. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111(4), 2329-2338 (2008). (Pubitemid 351451441)
37. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl Acad. Sci. USA 103(45), 16870- 16875 (2006). (Pubitemid 44737345)
38. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. 10(11), 1187-1189 (2004). (Pubitemid 39540433)
39. Copland M, Hamilton A, Elrick LJ et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107(11), 4532-4539 (2006). (Pubitemid 43801382)
40. Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 118(8), 2035-2043 (2011).
41. Gontarewicz A, Balabanov S, Keller G et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111(8), 4355-4364 (2008).
42. Quintás-Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin. Pharmacother. 9(6), 1029-1037 (2008). (Pubitemid 351593746)
43. Cortes JE, Kim D-W, Pinilla-Ibarz J et al. The PACE Study Group. Initial findings From the PACE trial: a pivotal Phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Blood 118, Abstract 109 (2011).
44. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin. Investig. Drugs 17(6), 865-878 (2008). (Pubitemid 351864324)
45. Cortes J, Talpaz M, Bixby D et al. A Phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood 116(21), Abstract 210 (2010).